Atossa shareholders approve 15:1 reverse stock split effective Feb 2, 2026

ATOSSA THERAPEUTICS, INC.

Approved at Special Meeting: 33.7M for, 27.9M against, 0.1M abstentions; no broker non-votes.
Board set ratio at 15:1; effective 12:01 a.m. ET on Feb 2, 2026; trading begins on split-adjusted basis same day.
No fractional shares issued; cash paid in lieu based on Jan 30, 2026 closing price adjusted for split ratio.
Proportionate adjustments to outstanding equity awards, exercise prices, and Series B Preferred conversion price.
Par value remains $0.18 per share; CUSIP changes to 04962H704; ticker ATOS unchanged.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ATOSSA THERAPEUTICS, INC.: Approved a 15:1 reverse stock split of common stock and filed an amendment to the Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, effective February 2, 2026 (effective 2026-02-02).

Change: charter amendment
Effective: 2026-02-02

Exact text from the filing

the Company filed an amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), with the Secretary of State of the State of Delaware (the “Amendment”).

View on SEC.gov

Browse all governance changes →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-021727

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.